Pfizer (PFE) Stock Looks Attractive for Income Investors
Pfizer ($PFE) stock looks attractive for income investors because of its well-covered dividend and modest valuation. The drug maker’s shares have o...
Johnson & Johnson (JNJ)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 14,837,126 | $3,927,981,007 | +12% | 1.13% |
| 2. | Yacktman Asset Management Donald Yacktman | 1,261,078 | $333,857,790 | +1% | 3.99% |
| 3. | Markel Gayner Asset Management Tom Gayner | 610,800 | $161,703,191 | 1.26% | |
| 4. | RWC Asset Management Tord Stallvik (Ceo) | 267,730 | $70,878,840 | +3% | 2.63% |
| 5. | Levin Capital Strategies John A. Levin | 206,133 | $54,571,784 | +1% | 3.84% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $206.15 | 1,250 | $257,687.50 | 1,849 | 2025-11-26 | Filing | |
| $145.53 | 100 | $14,553.00 | 250 | 2024-04-30 | Filing | |
| $147.22 | 1,000 | $147,220.00 | 1,000 | 2024-12-12 | Filing | |
| $127.69 | 500 | $63,843.00 | 16,030 | 2020-03-13 | Filing | |
| $141.28 | 5,000 | $706,399.00 | 5,000 | 2019-12-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $274.74 | 22,527 | $6,189,067.98 | 25,447 | 2026-09-02 | Filing | |
| $274.74 | 11,070 | $3,041,371.80 | 25,447 | 2026-09-02 | Filing | |
| $263.36 | 15,000 | $3,950,400.00 | 194,451 | 2026-08-17 | Filing | |
| $261.00 | 102,315 | $26,704,215.00 | 275,967 | 2026-08-13 | Filing | |
| $262.00 | 20,976 | $5,495,712.00 | 378,282 | 2026-08-13 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 65,497,363 | $17,301,766,484 | 0.9% | |
| 2. | 21,579,635 | $5,712,992,899 | 0.94% | |
| 3. | 14,996,077 | $3,970,271,770 | 0.72% | |
| 4. | 13,968,174 | $3,697,934,385 | 1.02% | |
| 5. | 12,048,226 | $3,189,647,352 | 0.64% |
News See All
Intuitive Surgical Stock (ISRG) Still Looks Worth Its Premium
Intuitive Surgical ($ISRG) stock still looks worth its premium, in my view. The robotic surgery specialist grew Q3 revenue 22%, while hospitals kep...
10 Most Undervalued Dividend Growth Stocks According to Hedge Funds
Dividend-paying stocks can be an important part of a long-term investment portfolio because they let investors earn steady income while also participating in the stock market's growth.
Johnson & Johnson (JNJ) Reports 69% Tumor Response Rate for Prostate Cancer Drug
Johnson & Johnson ($JNJ) has reported promising early results for its experimental prostate cancer pill, JNJ-6143, which has excited the oncology w...
Johnson & Johnson (JNJ) Drugs Lift Guidance, but Is 23 Times Earnings Fair?
Johnson & Johnson (NYSE:JNJ) raised its 2026 forecast earlier this month.
11 Best Cancer Stocks to Invest In Now
Cancer’s Burden Keeps the Search for Better Treatments Urgent For cancer patients, progress means more time, fewer side effects, and a better chance of recovery.
Johnson & Johnson (JNJ): Are Its Medical Device Deals Paying Off?
Johnson & Johnson (NYSE:JNJ) is turning acquired heart technologies into growing sales.
Johnson & Johnson (JNJ) Has Improved, but I’m Holding Off after the Rally
Johnson & Johnson’s ($JNJ) rally has me holding off, despite an improving business. The global healthcare products maker raised its full-year guida...
10 Best Big Name Stocks to Buy According to Financial Media
Wall Street has had a remarkable run in 2026, but the latest market turbulence is a reminder of how quickly investor sentiment can change.
Johnson & Johnson’s Dividend Machine Is Running. Can Earnings Keep Up?
Johnson & Johnson (NYSE:JNJ) stands out in the healthcare world for a reason.
Hedge Fund Resource Center